Research and Markets (http://www.researchandmarkets.com/research/vsr4qc/tachycardia) has announced the addition of the "Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013" report to their offering.

'Tachycardia (Tachyarrhythmias) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tachycardia (Tachyarrhythmias), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tachycardia (Tachyarrhythmias).

Scope

  • A snapshot of the global therapeutic scenario for Tachycardia (Tachyarrhythmias).
  • A review of the Tachycardia (Tachyarrhythmias) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Tachycardia (Tachyarrhythmias) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Companies Mentioned

  • Aop Orphan Pharmaceuticals AG

Drug Profiles

  • landiolol
  • acetazolamide sodium
  • atomoxetine hydrochloride
  • entacapone
  • mecamylamine hydrochloride

For more information visit http://www.researchandmarkets.com/research/vsr4qc/tachycardia

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular